Thus, in the Chinese Society of Clinical Oncology (CSCO) guidelines of NPC in 2020, concurrent anti-EGFR agents alone or a combination of concurrent anti-EGFR agents and chemotherapy were both recommended (category 3 recommendation) (13). The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.